52 Additional Major Adverse Reactions
Other Minor Cases
[Asia Economy Reporter Cha Min-young] As the number of COVID-19 vaccine recipients in South Korea increases, reports of adverse reactions have also risen by about 4,000 cases over the past two days.
According to the COVID-19 Vaccination Response Promotion Team (Promotion Team) on the 20th, a total of 4,114 new cases were reported to health authorities between the 18th and 19th, suspected of adverse reactions following vaccination.
Daily reports of adverse reactions were 2,732 on the 18th and 1,382 on the 19th. By vaccine type, there were 2,584 cases for Pfizer, 1,266 for Moderna, 230 for AstraZeneca (AZ), and 34 for Janssen.
There were 5 new death reports. Among the deceased, 4 had received the Pfizer vaccine, and 1 had received the AstraZeneca vaccine. A causal relationship between vaccination and death has not yet been confirmed, and the Promotion Team plans to evaluate the association through expert review.
Reports suspected of severe systemic allergic reactions, known as 'anaphylaxis,' increased by 15 cases. Of these, 8 were Pfizer recipients and 7 were Moderna recipients.
There were 52 major adverse reaction cases, including those of 'special interest,' ICU admission, life-threatening conditions, permanent disability, and sequelae (33 Pfizer, 10 AstraZeneca, 9 Moderna). The remaining cases were reports of common post-vaccination symptoms such as injection site redness, pain, swelling, muscle pain, and headache.
Since vaccinations began domestically on February 26, the cumulative number of suspected adverse reaction reports has reached 244,038 cases. Compared to the cumulative number of vaccinations (57,259,535 doses) as of midnight that day, this represents about 0.43%.
As of midnight that day, the total cumulative death reports numbered 652, with Pfizer at 341, AstraZeneca at 285, Moderna at 15, and Janssen at 11 cases, in that order.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
